

# **NCVHS Hearing on Meaningful Use October 13-14, 2009**

**Current measure development, endorsement, and adoption  
process**



**Karen Kmetik, PhD  
Vice President  
Performance Improvement  
American Medical Association and  
Physician Performance for Improvement®**



# Outline



1. PCPI Model – integrating quality measures into EHRs
2. Proposal to track progress/readiness
3. Areas of focus/gaps

Toward: Timely Data that Make a Difference

# PCPI Model



## 1. Develop and Maintain Clinically-relevant Quality Measures

- AMA-convened Physician Consortium for Performance Improvement® (PCPI)
- Growing portfolio of measures across specialties and subspecialties

## 2. Develop and Maintain EHR Specifications for Measures

- Level 1 EHR specifications – all available code sets, algorithms, rules
- Level 2 EHR specifications – in SDO-approved format

## 3. Evaluate EHR Specifications with Vendors and Physician Users


- AMA/NCQA/HIMSS-EHRA Collaborative
- Actionable at the point of care – physicians
- Unambiguous specifications – vendors

## 4. Implement Real-world “Incubator Groups” to Test Feasibility and Validity

- **Cardio-HIT**
  - 2 national measurement sets, different specialties, different EHR products
- **Alliance of Chicago Community Health Services**
  - 5 national measurement sets, 1,000 clinical users, single EHR product

# PCPI Model

American Medical Association and the AMA-convended Physician Consortium for Performance Improvement®



# 1. Develop and Maintain Clinically-relevant Quality Measures



## *Example:*

### ***Complete measurement set for Heart Failure***

- Co-developed by the PCPI, American College of Cardiology Foundation and the American Heart Association
- New measures to take advantage of rich data source, e.g., Persell 2009

### ***1 measure in the set:***

**ACE Inhibitor or ARB Therapy for Left Ventricular Systolic Dysfunction (LVSD)**

## 2. Develop and Maintain EHR Specifications for Measures



*Example: ACE Inhibitor or ARB Therapy for LVSD*

**Level 1 EHR Specifications:** all available code sets, algorithms for calculations, and “rules”

### **Denominator**

- **ICD-9: Diagnosis Codes**
- **SNOMED-CT Codes: Diagnosis codes**
- **SNOMED-CT Codes: LVSD**
- **CPT: Encounter codes – ambulatory and in-patient**

### **Numerator**

- **Rx Norm** and **NDC Codes** for ACE Inhibitor and ARBs to be determined
- **CPT-II Codes**

### **Exceptions**

- **SNOMED-CT Codes**
- **CPT-II Codes**

**Level 2 EHR Specifications:** unambiguous in SDO-approved format

### 3. Evaluate EHR Specifications with Vendors and Physician Users



AMA/NCQA/HIMSS-EHRA Collaborative

Vendors

- Prototype for Level I and Level II specifications  
Unambiguous?

Physicians

- Clinically meaningful? Timely?

## 4. Implement Real-world “Incubator Groups” to Test Feasibility and Validity

### Cardio-HIT: Different specialties, practice sizes and EHR products in use

| Site Name   | Location          | EHRs product           |
|---|-------------------|------------------------|
| Fox Prairie Medical Group<br>Primary Care                         | St. Charles, IL   | NextGen                |
| Midwest Heart Specialists<br>Cardiology                           | Lombard, IL       | Hybrid EHRs            |
| North Ohio Heart Center<br>Cardiology/Primary Care                | Lorain, OH        | Allscripts Touchworks™ |
| Northwestern Medical Faculty Foundation<br><i>(Phase I only)</i>  | Chicago, IL       | Epic                   |
| Physicians Health Alliance (PHA)<br>Primary Care                  | Scranton, PA      | GE Centricity          |
| University of Pittsburgh Medical Center<br>(UPMC)<br>Primary Care | Pittsburgh,<br>PA | Epic                   |

# Implement “Incubator Group” to Test Feasibility and Validity – Cardio-HIT\*



**Example:** ACE Inhibitor or ARB Therapy for LVSD

- **Finding:** Discrepancies between NDC codes in measure specifications and NDC code updates in practice (RxNorm not widely used)
  
- **Data Warehouse**
  - **Performance Rate: 80.38%**
    - 2007 PQRI Measure #5: 49.26%
  - **Applied Exception Rate: 6.17%**
  
- **Sample Data Abstraction**
  - **Applied Exception Reporting Agreement: 100%**
  - **Measure Met Agreement: 90.48%**
  - **Apparent Quality Failures Agreement: 19.53%**

**Note:** Preliminary data - please do not cite

# Track Progress for each Specialty



**Example:** ACE Inhibitor or ARB Therapy for LVSD

|                         | PCPI Clinically Relevant Measure/<br>NQF-endorsed or<br>in Process | Level 1 and 2<br>Specs Available | EHR Vendor/<br>Physician User<br>Review | Incubator Group<br>Testing | Queryable Fields<br>and Data Coded  |
|-------------------------|--|----------------------------------|---|----------------------------|---|
| Process                 | √  | √                                | √                                       | √                          | Outstanding: Rx<br>Norm, NDC<br>Automatic<br>population of<br>ejection fraction |
| Intermediate<br>Outcome |  |                                  |   |                            |   |
| Outcome                 |  |                                  |   |                            |   |
| Cost/ utilization       |  |                                  |   |                            |   |

# Areas of Focus to Fill Gaps



- Work with specialties to “round out” measurement sets to include process, intermediate outcomes, outcomes, and cost/utilization – good foundation exists
- New areas:
  - Ambulatory care transitions
  - Pediatrics
  - Sub-specialties

# Summary



Using PCPI Model,

Continue to:

- Work with each specialty and subspecialty to assure set of meaningful measures for meaningful EHR use (each set to include process, outcomes, appropriateness)
- Continue to develop Level I and Level II specifications
- Continue to “vet” with EHR vendors and physicians
- Expand “incubator groups” to test
- Track progress to determine “readiness”



Karen Kmetik, PhD  
[Karen.Kmetik@ama-assn.org](mailto:Karen.Kmetik@ama-assn.org)  
312-464-4221